Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 1667 results found since Jan 2013.

Toxicological Exploration of Peptide-based Cationic Liposomes in siRNA Delivery
Publication date: Available online 25 March 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Yanyan Zhu, Yao Meng, Yinan Zhao, Jie Zhu, Hong Xu, Enxia Zhang, Lei Shi, Linying Du, Guoliang Liu, Chuanmin Zhang, Xiaodong Xu, Xiaohui Kang, Yuhong Zhen, Shubiao ZhangAbstractThe toxicology of cationic liposomes was explored to advance clinical trials of liposome-mediated gene therapy through the analysis of a peptide cationic liposome with DOTAP as a positive control. We first investigated the delivery of luciferase siRNA by several peptide liposomes in mice bearing lung cancer A549 cell xenografts. Of these, a catio...
Source: Colloids and Surfaces B: Biointerfaces - March 28, 2019 Category: Biochemistry Source Type: research

Ultrasound-sensitive siRNA-loaded nanobubbles fabrication and antagonism in drug resistance for NSCLC
In this study, we have prepared nanobubbles loaded PDLIM5 siRNA (PDLIM5siRNA-NBs) to investigate the transfection efficiency and their antagonism in drug resistance in combination with ultrasound irradiation for non-small-cell lung cancer (NSCLC). Research results show that the PDLIM5 siRNA are effectively bound to the shell of NBs with a mean diameter of 191.6 ± 0.50 nm and a Zeta potential of 11.8 ± 0.68 mV. And the ultrasonic imaging indicated that the PDLIM5 siRNA NBs maintain the same signals as the microbubbles (SonoVue). Under the optimized conditions of 0.5 W/m2 ultrasound intensity and 1 min irradiation duration...
Source: Drug Delivery - December 29, 2021 Category: Drugs & Pharmacology Authors: Chunhong Su XiaoJun Ren Fang Yang Bin Li Hao Wu Hui Li Fang Nie Source Type: research

< em > In vitro < /em > synergistic activity of cisplatin and EGFR-targeted nanomedicine of anti-Bcl-xL siRNA in a non-small lung cancer cell line model
In this study, anti-Bcl-xL siRNA were formulated within an EGFR-targeted nanomedicine with scFv ligands (NM-scFv) and its activity was tested in the non-small cell lung cancer (NSCLC) cell line H460. The obtained NMs-scFv anti-Bcl-xL were suitable for intravenous injection with sizes around 100 nm, a high monodispersity level and good siRNA complexation capacity. The nanocomplex's functionalization with anti-EGFR scFv ligands was shown to allow an active gene delivery into H460 cells and led to approximately 63% of gene silencing at both mRNA and protein levels. The NM-scFv anti-Bcl-xL improved the apoptotic activity of ci...
Source: Cancer Control - November 24, 2022 Category: Cancer & Oncology Authors: Phuoc Vinh Nguyen Katel Herv é-Aubert Laurie Lajoie Yoann Misericordia Igor Chourpa St éphanie David Emilie Allard-Vannier Source Type: research

Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells
Background: Small cell lung cancer (SCLC) is a special kind of lung cancers, lymph or blood metastasis of SCLC usually occurs in early stage. Studies in breast and colon cancer showed over expression of SATB1 could promote tumor cell growth and inhibit apoptosis. Therefore, we studied the expression of SATB1 in SCLC. Methods: The level of SATB1 was analyzed in SCLC tissues, metastatic lymphoid nodes and adjacent normal lung tissues by immunohistochemistry. Meanwhile, small interfering SATB1-targeting RNA was constructed and transfected into human SCLC cell line NCI-H446 to evaluate the effects of SATB1-siRNA on cell prolif...
Source: Cancer Cell International - February 5, 2013 Category: Cancer & Oncology Authors: Bo HuangHongli ZhouXiaodong WangZhiliang Liu Source Type: research

Expression of HAb18G in non-small lung cancer and characterization of activation, migration, proliferation, and apoptosis in A549 cells following siRNA-induced downregulation of HAb18G.
Abstract HAb18G, a novel cancer biomarker, has been shown to be involved in the progression of malignancy by regulating expression of vascular endothelial growth factor (VEGF) and matrixmetalloproteinases (MMPs). The goal of this study was to evaluate the role of HAb18G in the biology of NSCLC and to determine its potential as a therapeutic target. HAb18G protein expression was detected by immunohistochemistry in 150 NSCLC tissues. The results showed that HAb18G protein expression was associated with tumor diameter, lymph node status, tumor stage, and poor prognosis (P < 0.05). Multivariate analysis showed th...
Source: Molecular and Cellular Biochemistry - September 8, 2013 Category: Biochemistry Authors: Xu X, Liu S, Lei B, Li W, Lin N, Sheng W, Huang A, Shen H Tags: Mol Cell Biochem Source Type: research

Abstract 4475: IL-4 receptor-targeted delivery of liposomal doxorubicin and siRNA to tumor
Targeted delivery of imaging agents and therapeutics to tumors would provide early detection and increased therapeutic efficacy against cancer. Using phage displayed-random peptide libraries, we have identified IL4RPep-1 (IL-4 receptor-binding peptide-1), CRKRLDRNC, that binds to IL-4 receptor (IL4R). IL4R is over-expressed on many types of cancer cells including lung cancer and breast cancer. Peptides have smaller size and in turn may exert better tissue penetration than bulky antibodies. IL4RPep-1 bound to H226 lung tumor cells that over-express IL4R, while little binding was observed in H460 lung tumor cells that expres...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Murugan, P. V. S., Rangaswamy, G. G., Chi, L., Padmanaban, G., Baek, M.-C., Kim, I.-S., Park, R.-W., Lee, B.-H. Tags: Cancer Chemistry Source Type: research

Abstract A47: IL-4 receptor-targeted delivery of liposomal doxorubicin and siRNA to tumor
Targeted delivery of imaging agents and therapeutics to tumors would provide early detection and increased therapeutic efficacy against cancer. Using phage displayed-random peptide libraries, we have identified IL4RPep-1 (IL-4 receptor-binding peptide-1), CRKRLDRNC, that binds to IL-4 receptor (IL4R). IL4R is over-expressed on many types of cancer cells including lung cancer and breast cancer. Peptides have smaller size and in turn may exert better tissue penetration than bulky antibodies. IL4RPep-1 bound to H226 lung tumor cells that over-express IL4R, while little binding was observed in H460 lung tumor cells that expres...
Source: Cancer Research - January 12, 2015 Category: Cancer & Oncology Authors: Padmanaban, G., Vadevoo, S. M. P., Chi, L., Lee, B.-H. Tags: Translational and Therapeutic Potential of the Tumor Microenvironment Source Type: research

Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA molecules
Conclusions: The inhibition of EGF system blockade with siRNA technique appears to be more effective strategy in cancer treatment in vitro, as compared to erlotinib, since this effect is probably EGFR gene mutation-independent. However, we have not definitively proved if it resulted in increased tumor cell immunogenicity.
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Gawronski, M., Kopinski, P., Jankowski, M., Goede, A., Szpechcinski, A., Chorostowska, J. Tags: 11.1 Lung Cancer Source Type: research

Charge reversible calcium phosphate lipid hybridnanoparticle for siRNA delivery.
Authors: Cai RQ, Liu DZ, Cui H, Cheng Y, Liu M, Zhang BL, Mei QB, Zhou SY Abstract Bcl-2 gene is an important target to treat lung cancer. The small interference RNA (siRNA) of Bcl-2 gene (siBcl-2) can specifically silence Bcl-2 gene. However, naked siBcl-2 is difficult to accumulate in the tumor tissue to exert its activity. In this paper, a calcium phosphate lipid hybrid nanoparticle that possessed charge reversible property was prepared to enhance the activity of siBcl-2 in vivo. The average diameter and zeta potential of siBcl-2 loaded calcium phosphate lipid hybrid nanoparticles (LNPS@siBcl-2) were 80 nm and -...
Source: Oncotarget - May 19, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC
Publication date: Available online 12 May 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Dhananjay Suresh, Ajit Zambre, Soumavo Mukherjee, Shreya Ghoshdastidar, Yuexu Jiang, Trupti Joshi, Anandhi Upendran, Raghuraman KannanAbstractNon-small cell lung cancer (NSCLC) is the leading cause of cancer mortality with the 5-year survival rate remains a dismal 16% for the past 40 years. Drug resistance is a major obstacle to achieving long-term patient survival. Identifying and validating molecular biomarkers responsible for resistance and thereby adopting multi-directional therapy is necessary to imp...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 12, 2019 Category: Nanotechnology Source Type: research

Co-delivery of paclitaxel and survivin siRNA with cationic liposome for lung cancer therapy
Publication date: Available online 3 October 2019Source: Colloids and Surfaces A: Physicochemical and Engineering AspectsAuthor(s): Chuanmin Zhang, Shubiao Zhang, Defu Zhi, Yinan Zhao, Shaohui Cui, Jingnan CuiAbstractThis work designed a new delivery system (L-PTX-PSur), which could efficiently co-deliver paclitaxel (PTX) and survivin siRNA (Sur) to overcome the dose-limiting toxicity by effectively accumulating PTX in tumor and obtain enhanced therapy by synergistic effect. In this co-delivery system, protamine was selected to condense siRNA into a compacted ‘core’, and a carbamate-linked cationic lipid was used to de...
Source: Colloids and Surfaces A: Physicochemical and Engineering Aspects - October 4, 2019 Category: Chemistry Source Type: research

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Abstract Non-small cell lung cancer (NSCLC) is a common diagnosed cancer disease worldwide and its management remains a challenge. Synergistic cancer therapeutic strategy is interesting for multiple advantages, such as excellent targeting accuracy, low side effects, and promoted therapeutic efficiency. In the present study, myricetin (Myr)-loaded mesoporous silica nanoparticles (MSN) combined with multidrug resistance protein (MRP-1) siRNA was prepared. The surface of the synthesized nanoparticles was modified with folic acid (FA) to promote the therapeutic efficiency of Myr for the treatment of NSCLC. The collect...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 21, 2020 Category: Drugs & Pharmacology Authors: Song Y, Zhou B, Du X, Wang Y, Zhang J, Ai Y, Xia Z, Zhao G Tags: Biomed Pharmacother Source Type: research

Downregulation of LRP/LR with siRNA inhibits several cancer hallmarks in lung cancer cells
FEBS Open Bio. 2022 Dec 29. doi: 10.1002/2211-5463.13544. Online ahead of print.ABSTRACTThe incidence and mortality rates of cancer are growing rapidly worldwide, with lung cancer being the most commonly occurring cancer in males. Human carcinomas circumvent the inhibitory pathways induced by DNA damage and senescence through the upregulation of telomerase activity. The 37 kDa/67 kDa laminin receptor (LRP/LR) is a cell surface receptor which plays a role in several cancer hallmarks, including metastasis, angiogenesis, cell viability maintenance, apoptotic evasion and mediating telomerase activity. We have previously shown ...
Source: Cancer Control - December 29, 2022 Category: Cancer & Oncology Authors: Monique J Bignoux Tyrone C Otgaar Martin Bernert Stefan F T Weiss Eloise Ferreira Source Type: research

Silencing NACK by siRNA inhibits tumorigenesis in non-small cell lung cancer via targeting Notch1 signaling pathway.
This study demonstrates that interference of NACK inhibits NSCLC progression through Notch1 signaling pathway and targeting NACK may be an effective approach for NSCLC therapy. PMID: 26782286 [PubMed - as supplied by publisher]
Source: Oncology Reports - January 21, 2016 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research